When Inovio Pharmaceuticals (INO) had its PPS doubling spike from 6/23-6/26, in those four days, 591 million shares were traded. There are only 167 million INO outstanding share. This means that there was a total share turnover of 3.5 times. That is when INO got the $71 million Defense contract for Cellectra. While the last three days of GNBT volume has been climbing (1.4m, 2.2m and 2.8m today so far), this still only represents about 6% of the outstanding shares (107m). Not enough BID pressure to keep the deviants from their devious actions. I just don’t know what to think of the ones that are continuing to SELL at .20ish. I just hope it is not small time investors, like us, being bamboozled out of their holdings.